- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials Sponsored by COUR Pharmaceuticals Development Company, Inc.
Total 533 results
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)United States, Australia, Belgium, Germany, Italy, Poland, Romania, United Kingdom, Argentina, Canada, France, Netherlands, Russian Federation
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAttention Deficit Hyperactivity Disorder | Attention Deficit DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedMultidrug Resistant TuberculosisPhilippines, South Africa
-
Otsuka Pharmaceutical Development & Commercialization...CompletedPolycystic Kidney, Autosomal DominantBelgium, Germany, Italy, Spain, Sweden, United States, Canada, Australia, Netherlands, Czechia, Poland, Denmark, Israel, Hungary, Russian Federation, South Africa, United Kingdom, Romania, Argentina, Norway
-
Otsuka Pharmaceutical Development & Commercialization...TerminatedSchizophrenia | Major Depressive Disorder | Bipolar 1 DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedNervous System Diseases | Schizophrenia | Mental DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedChronic Kidney Disease | Autosomal Dominant Polycystic Kidney DiseaseAustralia, Belgium, Italy, Spain, Sweden, United States, Canada, Netherlands, Czechia, Poland, Germany, Russian Federation, Hungary, Israel, Puerto Rico, Argentina, Denmark, South Africa, United Kingdom, Norway, France, Romania
-
Otsuka Pharmaceutical Development & Commercialization...Completed
-
Otsuka Pharmaceutical Development & Commercialization...CompletedMental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, MajorUnited States, Poland, Serbia, Russian Federation, Germany, Canada, France
-
Otsuka Pharmaceutical Development & Commercialization...CompletedPediatric | Multidrug Resistant TuberculosisPhilippines, South Africa
-
Otsuka Pharmaceutical Development & Commercialization...TerminatedAdolescent Schizophrenia | Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic FeaturesIndia, United States, Bulgaria, Croatia, Hungary, Malaysia, Philippines, Poland, Romania, Russian Federation, Serbia, Taiwan, Ukraine
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaUnited States, Croatia, Serbia, Bulgaria, India, Korea, Republic of, Philippines, Romania, Russian Federation, Slovakia, Taiwan, Ukraine
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Terminated
-
Otsuka Pharmaceutical Development & Commercialization...WithdrawnNervous System Diseases | Schizophrenia | Mental Disorder | Bipolar 1 DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaUnited States, India, Malaysia, Philippines, Romania, Russian Federation, Taiwan
-
Otsuka Pharmaceutical Development & Commercialization...TerminatedHyponatremia | Inappropriate ADH Syndrome | Dilutional HyponatremiaUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Completed
-
Otsuka Pharmaceutical Development & Commercialization...Completed
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAdvanced CancerUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedBipolar DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Completed
-
Otsuka Pharmaceutical Development & Commercialization...CompletedUlcerative ColitisUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedCongestive Heart FailureUnited States, Canada, Netherlands, United Kingdom, France, Spain, Germany, Switzerland, Italy, Brazil, Argentina, Russian Federation, Belgium, Romania, Czech Republic, Norway, Poland, Sweden
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophrenia | Mania
-
Aurinia Pharmaceuticals Inc.Labcorp Drug Development IncRecruiting
-
Zona Health, IncResearch & Development Concierge CompanyTerminatedHypertension, SystolicUnited States
-
Kremers Urban Development CompanyWatson Laboratories, Inc.Completed
-
PETHEMA FoundationMillennium Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research...Completed
-
Otsuka Pharmaceutical Development & Commercialization...Quintiles, Inc.CompletedAcute SchizophreniaUnited States, Malaysia, Serbia, Ukraine, Romania, Puerto Rico, Colombia, Turkey
-
Novita Pharmaceuticals, Inc.Translational Drug DevelopmentCompletedBreast Cancer | Lung Cancer | Prostate Cancer | Colon Cancer | Pancreas Cancer | Liver Cancer | Ovary Cancer | Esophagus Cancer | Advanced or Metastatic Treatment-refractory Solid Tumor MalignanciesUnited States
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyRecruitingPrimary Hyperoxaluria Type 3 | Primary Hyperoxaluria Type 2 | Primary Hyperoxaluria Type 1 | Primary HyperoxaluriaUnited States, Canada, Lebanon, Turkey, United Kingdom, Germany, Italy, Japan, Poland, Spain, United Arab Emirates
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyCompleted
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyActive, not recruitingPrimary Hyperoxaluria Type 3United States, Germany, United Kingdom, Canada, Poland
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyCompleted
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyEnrolling by invitationKidney Diseases | Urologic Diseases | Genetic Disease | Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria Type 2 (PH2) | Primary Hyperoxaluria Type 3 (PH3)United States, France, Germany, Japan, Lebanon, Spain, United Kingdom, Australia, Canada, Italy, Netherlands, Norway, Turkey
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyAvailablePrimary Hyperoxaluria Type 1 (PH1)
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka America PharmaceuticalCompleted
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka America PharmaceuticalCompletedMajor Depressive DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka America PharmaceuticalCompletedBipolar I DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka America PharmaceuticalCompleted
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka America PharmaceuticalCompletedSchizophreniaAustria, United Kingdom, France, Spain, Sweden, Czech Republic, Denmark, Finland, Germany
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka America PharmaceuticalCompletedBipolar DisorderFrance, Portugal, Spain, Italy, Germany, South Africa, United Kingdom, United States, Russian Federation, Poland, Czech Republic, Hungary, Netherlands, Estonia, Australia, Bulgaria, Switzerland
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka America PharmaceuticalWithdrawnBipolar DisorderUnited States, India
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyRecruitingEnd Stage Renal Disease | Primary Hyperoxaluria Type 2 | Primary Hyperoxaluria Type 1Germany, Spain, United States, United Kingdom, Italy, United Arab Emirates, Lebanon, Morocco, France, Romania
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyActive, not recruitingAlpha 1-Antitrypsin DeficiencyUnited Kingdom, United States, Ireland, Belgium, New Zealand, Spain, Netherlands, Portugal, Canada, Australia, France, Austria, Germany, Sweden